Intarcia Therapeutics Stock
Intarcia Therapeutics is a biopharmaceutical company developing therapies for diseases that require long-term chronic treatment.
Sign up today and learn more about Intarcia Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Intarcia Therapeutics Stock
Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.
Pritzker Group Venture Capital
Scopely, Intarcia Therapeutics, project44, The Honest Company, Casper, Cameo, Heal, G2
CFO & Vice President, Finance and Operations
James M. Ahlers
Vice President, Global Regulatory Affairs and Quality
Vice President, General Counsel, and Chief Legal Officer
Vice President, Human Resources
James P. Brady
Head of Customer Experience & Outcomes (CXO)
Executive Director, DUROS® Manufacturing
Chief Operating Officer
Vice President, Chief Scientific Officer
Head of Discovery and Translational Medicine
Vice President, General Counsel, Corporate Secretary
- Oct, 14 2016These are the top 10 life sciences VC deals in Q3
- Jun, 13 2016Ethicon study reports bariatric surgery as effective treatment for Asian Indian type II patients | American Diabetes Assn. 2016 Scientific Sessions
- Jun, 7 2016Intarcia Announces Branding of the Medici Drug Delivery System™ -- A Platform of Technologies Key to Advancing its Pipeline of Once-Yearly Peptide and Antibody Fragment-Based Therapeutics in Poorly Controlled Chronic Diseases
- Jun, 1 2016Type 2 Diabetes Market Pipeline Covering 221 Companies for H1 2016 Reviewed in New Research Report
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase